title: Inhibition of inducible nitric oxide synthase expression by endothelin in rat glial cells prepared from the neonatal rat brain.
abstract: In primary cultured rat glial cells, a combination of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) stimulates production of nitrite via expression of the inducible form of nitric oxide synthase (iNOS). In these cells, simultaneous addition of endothelin (ET) decreased iNOS expression and nitrite accumulation induced by TNF-alpha/IL-1beta. The inhibitory effect of ET on TNF-alpha/IL-1beta-stimulated iNOS expression appears to be mediated by ET(B) receptors, because (1) both ET-1 and ET-3 inhibited the effects of TNF-alpha/IL-1beta on iNOS expression and nitrite accumulation, (2) a selective ET(B) receptor agonist, Suc-[Glu(9),Ala(11,15)]-ET-1 (8-21) (IRL1620), decreased the effects of TNF-alpha/IL-1beta, and (3) a selective ET(B) receptor antagonist, N-cis-2,6-dimethylpiperidinocarbonyl-L-gamma-methylleucyl-D- 1-methoxycarbonyltryptophanyl-D-norleucine, abolished the inhibitory effects of ETs and IRL1620. Incubation of glial cells with lipopolysaccharide (LPS) caused an increase in iNOS expression. Simultaneous addition of ET-3 decreased the effects of LPS (10 and 100 ng/ml) on iNOS expression. Furthermore, cyclic AMP-elevating agents (dibutyryl cyclic AMP and forskolin) inhibited TNF-alpha/IL-1beta-induced and LPS-induced iNOS expression and nitrite accumulation. These findings suggest that ETs can decrease TNF-alpha/IL-1beta-induced and LPS-induced iNOS expression via ET(B) receptors and that cyclic AMP may be involved in this process.
authors.affiliation: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Oda
authors.forename: T
authors.initials: T
authors.lastname: Murayama
authors.forename: Y
authors.initials: Y
authors.lastname: Nomura
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001921:Brain / Q000201:enzymology*; D003994:Bucladesine / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000494:pharmacology*; D019334:Endothelin-3 / Q000494:pharmacology*; D016232:Endothelins / Q000494:pharmacology; D004790:Enzyme Induction; D007375:Interleukin-1 / Q000494:pharmacology; D009457:Neuroglia / Q000201:enzymology*; D019001:Nitric Oxide Synthase / Q000096:biosynthesis*; D009573:Nitrites / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000819:agonists / Q000502:physiology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D019334:Endothelin-3; D016232:Endothelins; D007375:Interleukin-1; D009573:Nitrites; D009842:Oligopeptides; D010446:Peptide Fragments; D010880:Piperidines; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D014409:Tumor Necrosis Factor-alpha; C074308:sovateltide; D005576:Colforsin; C086539:BQ 788; D003994:Bucladesine; D000242:Cyclic AMP; D019001:Nitric Oxide Synthase; D013755:Tetradecanoylphorbol Acetate